Stock Events

Stock Events

NeuBase Therapeutics 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow O7PA.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.92B
CRISPR Therapeutics is focused on developing gene-based medicines, directly competing with NeuBase's gene editing approach.
Editas Medicine
EDIT
Mkt Cap560.14M
Editas Medicine works on genome editing technologies, similar to NeuBase's platform, making them direct competitors in the gene therapy space.
Intellia Therapeutics
NTLA
Mkt Cap2.45B
Intellia Therapeutics is a leading developer of CRISPR gene editing treatments, competing in the same gene therapy market as NeuBase.
Beam Therapeutics
BEAM
Mkt Cap3.58B
Beam Therapeutics uses base editing, a form of gene editing, positioning it as a competitor in the precision genetic medicine field alongside NeuBase.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing with NeuBase in the development of genetic treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap41.76B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing with NeuBase's approach to gene silencing and editing.
Ionis Pharmaceuticals
IONS
Mkt Cap13.52B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, making it a competitor in the genetic medicine space.
Precision Biosciences
DTIL
Mkt Cap211.06M
Precision BioSciences utilizes its ARCUS genome editing platform to develop genetic treatments, competing with NeuBase's therapeutic approaches.
Voyager Therapeutics
VYGR
Mkt Cap228.39M
Voyager Therapeutics specializes in the development of gene therapies for neurodegenerative diseases, representing competition in the broader gene therapy field.

About

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Show more...
CEO
Dietrich Stephan
Employees
37
Country
United States
ISIN
US64132K1025

Listings

MU
DE
O7PA.MU
STU
DE
O7PA.STU

0 Comments

Share your thoughts

FAQ

What is NeuBase Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange NeuBase Therapeutics stocks are traded under the ticker O7PA.STU.
How many employees does NeuBase Therapeutics have?▼
As of July 10, 2026, the company has 37 employees.
In which sector is NeuBase Therapeutics located?▼
NeuBase Therapeutics operates in the Technology sector.
When did NeuBase Therapeutics complete a stock split?▼
NeuBase Therapeutics has not had any recent stock splits.
Where is NeuBase Therapeutics headquartered?▼
NeuBase Therapeutics is headquartered in Pittsburgh, United States.